CBL-514 vs Kybella: Apoptosis vs. Detergent Lysis in Injectable Fat Reduction

Kybella is a synthetic form of deoxycholic acid, a secondary bile acid that the body uses to emulsify dietary fat. Developed as ATX-101 by Kythera Biopharmaceuticals, it was approved by the FDA in 2015 for adults with moderate-to-severe submental fat – the fat under the chin. Its label describes it as a cytolytic drug: injected into tissue, it physically destroys cell membranes and causes the cells to lyse.

CBL-514 takes the opposite route. Caliway's protocols describe a formulation of curcumin and trans-resveratrol that inhibits the survival kinase DYRK1B in adipocytes, raises caspase-3 and the Bax/Bcl-2 ratio, and triggers apoptosis. The fat cell is not burst open; it dismantles itself and is removed by the immune system.

The table shows why the two products are often compared and why the comparison is easy to overstate. Both use the same kind of endpoint – a simultaneous two-grade improvement on a clinician scale and a patient scale – but on different body regions, with different molecules and at different stages of development.

Lysis is necrotic cell death. The cell's contents spill into the tissue and trigger inflammation; with deoxycholic acid that means swelling, pain and numbness at the injection site, and the detergent does not distinguish between a fat cell and a neighbouring skin, muscle or nerve cell. Precise placement is therefore part of the product's safety profile, which is one reason Kybella is used on a small, well-defined area.

Apoptosis is quieter. The cell shrinks, its DNA is cleaved in a controlled way, and macrophages clear the remains without a large inflammatory flare. Caliway's argument is that a cell-selective, apoptosis-based agent can be spread over a much larger area such as the abdomen without the tissue damage a detergent would cause. That argument rests on sponsor data; the Phase 3 programme, with several hundred participants per trial, is where it will be tested at scale.

Apoptosis-based fat reduction itself is not new. Cryolipolysis devices rely on the observation that controlled cooling makes adipocytes undergo apoptosis, followed by gradual clearance – first described in 2008. CBL-514 aims at a similar biological end point by pharmacological means, without a device.

Kythera's pivotal REFINE-1 and REFINE-2 trials and Caliway's Phase 2b trial CBL-0205 both reported the share of participants with a simultaneous two-grade improvement. The numbers below are as reported by the sponsors.

CBL-0205's figure is numerically higher, but the comparison has three caveats. The trials measured different anatomical regions on different scales. A Phase 2b result is not equivalent to a Phase 3 result, which typically includes more sites, a broader population and stricter conduct. And CBL-0205 had not been published in a peer-reviewed journal at the time of writing. Only the SUPREME-01 and SUPREME-02 readouts in 2027 will put CBL-514 on the same evidential level as Kybella's pivotal programme.

Approval alone does not guarantee that an aesthetic injectable succeeds. Qwo (collagenase clostridium histolyticum-aaes) was approved in the United States as the first injectable for cellulite, but on 6 December 2022 its maker Endo announced it would stop production and sales, citing market concerns about the extent and variability of bruising after treatment. Tolerability, not efficacy, ended it commercially.

That is relevant for CBL-514, whose early trials also report bruising and temporary yellow discoloration at the injection site. Caliway's own protocol frames the unmet need differently: it cites skin necrosis and infections caused by unregulated mesotherapy – non-approved fat-dissolving injections – as the problem an approved, standardised injectable would solve.

• Kybella and CBL-514 are different chemical classes with different mechanisms; neither is a peptide.
• Deoxycholic acid is an approved drug with a public label; CBL-514's ratio, formulation and specification remain confidential.
• No head-to-head trial exists. Responder rates from different programmes cannot be ranked against each other.
• The Phase 3 results expected in 2027 are the first data that can be compared with Kybella's pivotal evidence on equal terms.

There is no head-to-head trial. The products target different regions, and CBL-514's data so far come from Phase 2b, mostly company-reported. A fair comparison will only be possible once its Phase 3 results are published.

No. Deoxycholic acid is a bile-acid detergent that lyses cells. CBL-514's disclosed active ingredients are curcumin and trans-resveratrol, and its proposed mechanism is apoptosis through DYRK1B inhibition.

No such trial is registered. ClinicalTrials.gov lists CBL-514 studies in abdominal subcutaneous fat, cellulite, Dercum's disease and pharmacokinetics in healthy volunteers.

Endo announced on 6 December 2022 that it would cease production and sale of Qwo, citing concerns about bruising after treatment.

Yes. Cryolipolysis relies on cold-induced apoptosis of fat cells, followed by gradual clearance. CBL-514 aims at a comparable cellular outcome with a drug instead of a device.